Skip to content
← Back to this collection

PUBLICATIONS · 19805688

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2009 Nov 10
First author
Witzig TE

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Witzig TE
      type
      Author
    2. name
      Wiernik PH
      type
      Author
    3. name
      Moore T
      type
      Author
    4. name
      Reeder C
      type
      Author
    5. name
      Cole C
      type
      Author
    6. name
      Justice G
      type
      Author
    7. name
      Kaplan H
      type
      Author
    8. name
      Voralia M
      type
      Author
    9. name
      Pietronigro D
      type
      Author
    10. name
      Takeshita K
      type
      Author
    11. name
      Ervin-Haynes A
      type
      Author
    12. name
      Zeldis JB
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Witzig TE
      type
      Author
    2. name
      Wiernik PH
      type
      Author
    3. name
      Moore T
      type
      Author
    4. name
      Reeder C
      type
      Author
    5. name
      Cole C
      type
      Author
    6. name
      Justice G
      type
      Author
    7. name
      Kaplan H
      type
      Author
    8. name
      Voralia M
      type
      Author
    9. name
      Pietronigro D
      type
      Author
    10. name
      Takeshita K
      type
      Author
    11. name
      Ervin-Haynes A
      type
      Author
    12. name
      Zeldis JB
      type
      Author
    bibliography ids
    1. nci-bib-fc81ce3c062e2071aa0239b1
    book metadata
    content sha256
    f206cde0c382824d9909e9b8abacdb8e2ce56a32d94987caf9542a9b6a673458
    document type
    citation
    dois
    1. 10.1200/JCO.2008.21.1169
    electronic publication date
    display
    2009 Oct 5
    precision
    day
    year
    2009
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:19805688
    immutable id
    pubmed:19805688@f206cde0c382824d9909e9b8abacdb8e2ce56a32d94987caf9542a9b6a673458
    journal
    abbreviation
    J Clin Oncol
    issn electronic
    1527-7755
    issn print
    0732-183X
    issue
    32
    name
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    nlm unique id
    8309333
    pages
    5404-9
    volume
    27
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      19805688
      provenance
      batch id
      0706b5111d1451f52f74
      provider
      NCBI PubMed ESummary
      record sha256
      2f893141d4da01bff41ce16a6a4f74f3287412d7ec399ba064d36b734047c231
      response sha256
      98b7635e326dbc32198e6976da57b1b6c18df77505740dee0ce67d80260cda70
      retrieved at
      2026-09-09T23:46:29.215195+00:00
      publication date
      display
      2009 Nov 10
      precision
      day
      year
      2009
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Multicenter Study
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/19805688/
      title
      Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

      Preserved source evidence · Independent clinical review pending · Not medical advice